1265 related articles for article (PubMed ID: 19158438)
1. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
2. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
3. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
4. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
[TBL] [Abstract][Full Text] [Related]
5. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis.
Jiang LS; Zhang ZM; Jiang SD; Chen WH; Dai LY
J Bone Miner Res; 2008 Apr; 23(4):475-83. PubMed ID: 18052758
[TBL] [Abstract][Full Text] [Related]
6. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
7. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
8. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
Piatek S; Adolf D; Wex T; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S
Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
[TBL] [Abstract][Full Text] [Related]
9. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women.
Oh KW; Rhee EJ; Lee WY; Kim SW; Oh ES; Baek KH; Kang MI; Choi MG; Yoo HJ; Park SW
Clin Endocrinol (Oxf); 2004 Aug; 61(2):244-9. PubMed ID: 15272921
[TBL] [Abstract][Full Text] [Related]
10. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
Baek KH; Oh KW; Lee WY; Tae HJ; Rhee EJ; Han JH; Cha BY; Kim YJ; Lee KW; Son HY; Kang SK; Kim CC; Kang MI
Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
[TBL] [Abstract][Full Text] [Related]
11. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
[TBL] [Abstract][Full Text] [Related]
12. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer.
Mikosch P; Igerc I; Kudlacek S; Woloszczuk W; Gallowitsch HJ; Kresnik E; Stettner H; Grimm G; Lind P; Pietschmann P
Eur J Clin Invest; 2006 Aug; 36(8):566-73. PubMed ID: 16893379
[TBL] [Abstract][Full Text] [Related]
13. Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women.
Dai Y; Shen L
Chin Med J (Engl); 2007 Nov; 120(22):2017-21. PubMed ID: 18067789
[TBL] [Abstract][Full Text] [Related]
14. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
[TBL] [Abstract][Full Text] [Related]
15. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
[TBL] [Abstract][Full Text] [Related]
16. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
[TBL] [Abstract][Full Text] [Related]
17. The circulating concentration and ratio of total and high molecular weight adiponectin in post-menopausal women with and without osteoporosis and its association with body mass index and biochemical markers of bone metabolism.
Sodi R; Hazell MJ; Durham BH; Rees C; Ranganath LR; Fraser WD
Clin Biochem; 2009 Sep; 42(13-14):1375-80. PubMed ID: 19523465
[TBL] [Abstract][Full Text] [Related]
18. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
19. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
[TBL] [Abstract][Full Text] [Related]
20. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]